Effects of Belapectin, an Inhibitor of Galectin-3, in Patients with Nonalcoholic Steatohepatitis With Cirrhosis And Portal Hypertension

Hepatology

Randomized Placebo-Controlled Trial of Emricasan in Non-alcoholic Steatohepatitis (NASH) Cirrhosis with Severe Portal Hypertension

J Hepatol.

Garcia-Tsao G, Bosch J, Kayali Z, Harrison SA, Abdelmalek MF, Lawitz E, Satapathy SK, Ghabril M, Shiffman ML, Younes ZH, Thuluvath PJ, Berzigotti A, Albillos A, Robinson JM, Hagerty DT, Chan JL, Sanyal AJ, IDN-6556-14 Investigators.

doi: 10.1016/j.jhep.2019.12.010.

Hepatology

β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial

Lancet.

Villanueva C, Albillos A, Genescà J, Garcia-Pagan JC, Calleja JL, Aracil C, Bañares R, Morillas RM, Poca M, Peñas B, Augustin S, Abraldes JG, Alvarado E, Torres F, Bosch J

Hepatology

Effects of Albumin Treatment on Systemic and Portal Hemodynamics and Systemic Inflammation in Patients With Decompensated Cirrhosis

Gastroenterology.

Fernández J, Clària J, Amorós A, Aguilar F, Castro M, Casulleras M, Acevedo J, Duran-Güell M, Nuñez L, Costa M, Torres M, Horrillo R, Ruiz-Del-Árbol L, Villanueva C, Prado V, Arteaga M, Trebicka J, Angeli P, Merli M, Alessandria C, Aagaard NK, Soriano G, Durand F, Gerbes A, Gustot T, Welzel TM, Salerno F, Bañares R, Vargas V, Albillos A, Silva A, Morales-Ruiz M, Pavesi M, Jalan R, Bernardi M, Moreau R, Páez A, Arroyo V

doi: 10.1053/j.gastro.

Hepatology

Short-term hemodynamic effects of β-blockers influence survival of patients with decompensated cirrhosis

J Hepatol.

Tapias EA, Ardevol A, Garcia-Guix M, Montañés R, Pavel O, Cuyas B, Graupera I, Brujats A, Vilades D, Colomo A, Poca M, Torras X, Guarner C, Concepción M, Aracil C, Torres F, Villanueva C

doi: 10.1016/j.jhep.2020.03.048.

Hepatology

Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results from Randomized Ph III STELLAR Trials

J Hepatol.

Harrison SA, Wai-Sun Wong V, Okanoue T, Bzowej N, Vuppalanchi R, Younes Z, Kohli A, Sarin S, Caldwell SH, Alkhouri N, Shiffman ML, Camargo M, Li G, Kersey K, Jia C, Zhu Y, Djedjos CS, Subramanian GM, Myers RP, Gunn N, Sheikh A, Anstee QM, Romero-Gomez M, Trauner M, Goodman Z, Lawitz EJ, Younossi Z, STELLAR-3 and STELLAR-4 Investigators

doi: 10.1016/j.jhep.2020.02.027.

Hepatology

Abdominal surgery in patients with idiopathic noncirrhotic portal hypertension: a multicenter retrospective study

Hepatology.

Elkrief L, Ferrusquia-Acosta J, Payancé A, Moga L, Tellez L, Praktiknjo M, Procopet B, Farcau O, De Lédinghen V, Yuldashev R, Tabchouri N, Barbier L, Dumortier J, Menahem B, Magaz M, Hernández-Gea V, Albillos A, Trebicka J, Spahr L, De Gottardi A, Plessier A, Valla D, Rubbia-Brandt L, Toso C, Bureau C, Garcia-Pagan JC, Rautou PE

doi: 10.1002/hep.

Hepatology

Longitudinal Correlations Between MRE, MRI-PDFF, and Liver Histology in Patients with Nonalcoholic Steatohepatitis: Analysis of Data from a Phase 2 Trial of Selonsertib

J Hepatol.

Jayakumar S, Middleton MS, Lawitz EJ, Mantry PS, Caldwell SH, Arnold H, Diehl AM, Ghalib R, Elkhashab M, Abdelmalek MF, Kowdley KV, Djedjos CS, Xu R, Han L, Subramanian GM, Myers RP, Goodman ZD, Afdhal NH, Charlton MR, Sirlin CB, Loomba R

doi: 10.1016/j.jhep.2018.09.024.

Hepatology

Intragastric Balloon Placement Induces Significant Metabolic and Histologic Improvement in Patients With Nonalcoholic Steatohepatitis

Clin Gastroenterol Hepatol.

Bazerbachi F, Vargas EJ, Rizk M, Maselli DB, Mounajjed T, Venkatesh SK, Watt KD, Port JD, Basu R, Acosta A, Hanouneh I, Gara N, Shah M, Mundi M, Clark M, Grothe K, Storm AC, Levy MJ, Abu Dayyeh BK

doi: 10.1016/j.cgh.2020.04.068.

Hepatitis

Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension

J Hepatol.

Lens S, Baiges A, Alvarado E, LLop E, Martinez J, Fortea JI, Ibañez L, Mariño Z, Rodríguez-Tajes S, Gallego A, Bañares R, Puente Á, Albillos A, Calleja JL, Torras X, Hernández-Gea V, Bosch J, Villanueva C, García-Pagán JC, Forns X

doi: 10.1016/j.jhep.2020.05.050.

Related content

Randomized Placebo-Controlled Trial of Emricasan in Non-alcoholic Steatohepatitis (NASH) Cirrhosis with Severe Portal Hypertension

β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial

Effects of Albumin Treatment on Systemic and Portal Hemodynamics and Systemic Inflammation in Patients With Decompensated Cirrhosis

Short-term hemodynamic effects of β-blockers influence survival of patients with decompensated cirrhosis

Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results from Randomized Ph III STELLAR Trials

Abdominal surgery in patients with idiopathic noncirrhotic portal hypertension: a multicenter retrospective study

Longitudinal Correlations Between MRE, MRI-PDFF, and Liver Histology in Patients with Nonalcoholic Steatohepatitis: Analysis of Data from a Phase 2 Trial of Selonsertib

Intragastric Balloon Placement Induces Significant Metabolic and Histologic Improvement in Patients With Nonalcoholic Steatohepatitis

Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension